The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
复制标题
DOI：
10.1016/j.lungcan.2015.03.002
复制
发表时间：
2015-06
期刊：
影响因子：
5.3
通讯作者：
J. S. Park;Jaesang Lee;E. Y. Kim;J. Jung;S. K. Kim;Joon Chang;Dae Joon Kim;Chang Young Lee
中科院分区：
文献类型：
--
作者：
J. S. Park;Jaesang Lee;E. Y. Kim;J. Jung;S. K. Kim;Joon Chang;Dae Joon Kim;Chang Young Lee
目的成纤维细胞生长因子受体1（FGFR 1）在多种人类肿瘤中起重要作用。我们试图确定韩国小细胞肺癌（SCLC）患者中FGFR 1扩增的频率。此外，本发明还材料和方法收集2009年9月至2013年2月诊断为SCLC的158名韩国患者的肿瘤组织，并使用FGFR 1 FISH检测进行分析，该检测使用与染色体区域8 p12 - 13杂交的探针。结果和结论在3例（1.9%）广泛性疾病（艾德）患者中检测到FGFR 1扩增。多变量分析显示，在艾德患者中，FGFR 1扩增与依托泊苷联合顺铂或卡铂一线化疗的无病生存期较短相关（风险比[HR] = 7.1; 95%置信区间[CI] = 2.0-25.4;P= 0.003）。艾德患者中位总生存时间在有和无FGFR 1扩增的患者中分别为8.2和10.2个月（P= 0.37）。尽管与非小细胞肺癌或其他鳞状组织学恶性肿瘤相比，FGFR 1扩增在SCLC中很少见，但它与SCLC标准化疗后的生存率低相关。需要在大量SCLC患者中进行进一步研究以验证这些结果。我们的结果表明FGFR 1可能是SCLC的潜在治疗靶点，并且可以在临床试验中得到证实。
ObjectivesFibroblast growth factor receptor 1 (FGFR1) plays a critical role in many human cancers. We tried to identify the frequency ofFGFR1amplifications among Korean patients with small cell lung cancer (SCLC). Additionally, we examined the clinical significance ofFGFR1amplifications for overall survival (OS) and progression-free survival (PFS) among SCLC patients who received standard chemotherapies.Materials and methodsTumor tissues from 158 Korean patients diagnosed with SCLC from September 2009 to February 2013 were collected and analyzed using anFGFR1FISH assay with a probe that hybridized to chromosome region 8p12–8p11.23 (Abbott Molecular, Abbott Park, IL).Results and conclusionFGFR1amplification was detected in three patients (1.9%) harboring extensive disease (ED). A multivariate analysis showed that among the patients with ED,FGFR1amplification was associated with shorter disease-free survival to first-line chemotherapy with etoposide plus cisplatin or carboplatin (hazard ratio [HR] = 7.1; 95% confidence interval [CI] = 2.0–25.4;P= 0.003). The median overall survival time of the patients with ED was 8.2 and 10.2 months among patients with and withoutFGFR1amplification, respectively (P= 0.37). AlthoughFGFR1amplification is rare in SCLC compared to non-small cell lung cancer or other malignancies with squamous histology, it is associated with poor survival following standard chemotherapy in SCLC. Further studies in large cohorts of patients with SCLC are needed to verify these results. Our results imply thatFGFR1may be a potential therapeutic target in SCLC and it could be confirmed in a clinical trial.